ONEXTON Drug Patent Profile

When do Onexton patents expire, and what generic alternatives are available?

Onexton is a drug marketed by Bausch and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has twenty patent family members in fourteen countries.

The generic ingredient in ONEXTON is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Onexton

Annual sales in 2022 were $3mm indicating the motivation for generic entry (peak sales were $67mm in 2016).

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ONEXTON

International Patents:	20
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	9
Drug Prices:	Drug price information for ONEXTON
Drug Sales Revenues:	Drug sales revenues for ONEXTON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ONEXTON
What excipients (inactive ingredients) are in ONEXTON?	ONEXTON excipients list
DailyMed Link:	ONEXTON at DailyMed

See drug prices for ONEXTON

See drug sales revenues for ONEXTON

Recent Clinical Trials for ONEXTON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Derm Research, PLLC	Phase 4
Actavis Inc.	Phase 3
Taro Pharmaceuticals USA	Phase 1

See all ONEXTON clinical trials

Pharmacology for ONEXTON

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

Paragraph IV (Patent) Challenges for ONEXTON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ONEXTON	Gel	benzoyl peroxide; clindamycin phosphate	1.2%/3.75%	050819	1	2015-09-30
ONEXTON	Gel	benzoyl peroxide; clindamycin phosphate	1.2%/2.5%	050819	1	2012-12-20

US Patents and Regulatory Information for ONEXTON

ONEXTON is protected by eleven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014	AB	RX	Yes	Yes			Y
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014	AB	RX	Yes	Yes			Y
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014	AB	RX	Yes	Yes			Y
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014	AB	RX	Yes	Yes			Y
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014	AB	RX	Yes	Yes			Y

Expired US Patents for ONEXTON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	ONEXTON	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-002	Nov 24, 2014

International Patents for ONEXTON

See the table below for patents covering ONEXTON around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009255679	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Brazil	PI0913326	formulações farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água
Canada	2723029	FORMULATIONS PHARMACEUTIQUES TOPIQUES CONTENANT UNE FAIBLE CONCENTRATION DE PEROXYDE DE BENZOYLE EN SUSPENSION DANS DE L'EAU ET UN SOLVANT ORGANIQUE MISCIBLE AVEC L'EAU (TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT)
China	102056481	Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
European Patent Office	2299810	FORMULATIONS PHARMACEUTIQUES TOPIQUES CONTENANT UNE FAIBLE CONCENTRATION DE PEROXYDE DE BENZOYLE EN SUSPENSION DANS DE L'EAU ET UN SOLVANT ORGANIQUE MISCIBLE AVEC L'EAU (TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT)

Supplementary Protection Certificates for ONEXTON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221

Onexton (clindamycin phosphate 1% and benzoyl peroxide 3%) Market Dynamics and Financial Trajectory: Exclusivity, Pricing, Competition, and Revenue Outlook

Last updated: July 21, 2026

Onexton (clindamycin phosphate 1% and benzoyl peroxide 3%) is a dermatology fixed-dose combination gel for acne vulgaris. The product faces a typical US topicals lifecycle pattern: prescription penetration driven by guideline-aligned use, then gradual channel pressure from generics, therapeutics substitutes, and category shifts toward newer acne actives. Near-term financial trajectory is shaped less by a single monopoly and more by (1) generic and label-parallel competition risks for the combination, (2) payer formulary behavior for topical antibiotics plus benzoyl peroxide regimens, and (3) volume sensitivity to acne-severity distribution and prescriber switching.

What is Onexton, how does it make money, and what are the key market drivers?

Onexton is a topical acne medication combining an antibiotic (clindamycin phosphate) with benzoyl peroxide. It is positioned for acne vulgaris, leveraging the standard acne regimen logic: benzoyl peroxide helps reduce bacterial resistance and supports efficacy, while clindamycin provides targeted antibiotic activity.

What market dynamics matter most for topical acne fixed-dose combinations?

• Antibiotic stewardship and payer control: Topical antibiotics are constrained by stewardship and payer utilization management. Clinicians and payers tend to favor shorter antibiotic phases paired with benzoyl peroxide and/or retinoids.
• Formulary substitution risk: Fixed-dose combinations that overlap with the same actives in separate products can be clinically substituted (two-product regimens) even when the fixed-dose gel has adherence advantages.
• Channel mix: Acne is treated across dermatology, primary care, and telehealth. That distribution tends to emphasize formulary access and copay affordability.
• Adherence and tolerability: Benzoyl peroxide can drive irritation and discontinuation, which affects refill rates and persistence. Fixed-dose products can improve adherence versus “separate bottles,” but irritation remains a category limiter.
• Seasonality and acne epidemiology: Acne treatment demand is steady with modest cyclicality depending on skin exposure patterns and promotional cycles.

Where does Onexton fit in the US acne competitive set?

Onexton competes in a crowded topical acne market that includes:

• Topical retinoids (adapalene/tretinoin products, including combination retinoid strategies)
• Benzoyl peroxide monotherapies and combinations
• Topical antibiotic options (clindamycin or erythromycin products, including different vehicles)
• Combination regimens that replicate antibiotic plus benzoyl peroxide
• Non-antibiotic and newer-class prescriptions (where formularies push away from antibiotics)

How does Onexton’s exclusivity and patent landscape shape the financial trajectory?

A topical acne fixed-dose product is typically exposed to earlier competitive erosion than “blockbuster” systemic drugs, because:

• Topical antibiotic ingredients often have earlier foundational IP that expires well before modern branded combination products.
• Generic and private-label threats increase when the branded product’s exclusivity windows end.

Impact on revenue: Once combination-gel protection weakens, payers can switch to lower-priced options and prescribers shift by formulary mechanics rather than clinical preference.

What are the main IP and regulatory mechanisms that determine generic risk?

• Orange Book listed patents and exclusivity: When relevant patents expire, ANDA entrants can challenge via Paragraph IV (where applicable) and launch upon resolution.
• Data exclusivity: Brand-funded clinical data exclusivity is time-limited and can accelerate erosion if not backed by later patents.
• Litigation settlements: Settlement terms can create deferred launch dates or carve-outs.
• Vehicle/formulation IP: For combination topicals, formulation and manufacturing method patents can delay “authorized” alternatives even after actives become available.

Financial linkage: the “launch cliff” risk profile

For Onexton, the financial trajectory depends on whether remaining exclusivity constrains ANDA competition. The market impact pattern usually looks like:

• Pre-launch plateau: Stable branded prescriptions and pricing support while branded is the preferred combination on formularies.
• Post-expiration volatility: Immediate unit decline risk from automatic substitution and pharmacy bid systems.
• Margin compression: Even before full generic penetration, branded net price can fall due to managed entry agreements and rebates.

When does Onexton lose exclusivity in the US, and what launch scenarios apply?

Onexton’s post-exclusivity revenue path is typically shaped by whether generics enter as (1) combination-gel equivalents or (2) separate-ingredient regimens that mimic the clinical approach. The presence of multiple generic substitutes can accelerate price erosion beyond what a single competitor launch would do.

How many realistic generic entry scenarios exist?

1. ANDA for the fixed-dose combination gel: Direct substitution at pharmacy level.
2. ANDA for one active ingredient product plus OTC benzoyl peroxide access: Clinically feasible regimen shift.
3. Authorized generics / branded reversion: Could preserve a portion of revenue but narrows margin.
4. Different vehicle entry: May reduce substitution if irritation profiles differ, but payers may still drive switching.

What is the Orange Book status of Onexton?

Orange Book listings drive the generic entry timing. The most decision-relevant elements are:

• Patent list expiry dates
• Exclusivity codes for the NDA
• Any Orange Book-listed patents that are still active near forecast horizons

Without the underlying Orange Book listing dataset in this prompt, the exact patent numbers, expiry dates, and exclusivity periods cannot be stated accurately here.

What patent litigation affects Onexton, including Paragraph IV filings and settlements?

For a branded topical combination like Onexton, the key litigation items are:

• Whether ANDA filers challenged specific Orange Book patents via Paragraph IV
• Case filing dates, jurisdiction, and claimed patent scope
• Settlement-triggered “design-around” strategies and launch triggers

No litigation docket details are provided in this prompt, so litigation dates and settlement mechanics cannot be enumerated here.

How strong is the patent estate for Onexton’s formulations and method of use?

Topical acne products may have protection across:

• Formulation composition and stabilizers
• Release/vehicle technologies that affect irritation and permeation
• Use patents tied to dosing schedules, severity stratification, or combination regimen instructions

Because no patent list is included in this prompt, the number of active patents, their claims, and enforceability cannot be quantified without risking inaccuracies.

How does Onexton’s competitive landscape compare with other acne topical combinations?

Onexton’s differentiation is a fixed-dose combination with clindamycin plus benzoyl peroxide in a single product. Competitors match this either through:

• Fixed-dose combination products in similar categories
• Multi-bottle regimens covered by formularies at lower total cost
• Newer prescription non-antibiotic regimens that reduce stewardship pressure

What creates price pressure even before generic entry?

• Payer step therapy: Plans may require trials of lower-cost alternatives (often generic retinoids or benzoyl peroxide) before approving the antibiotic-containing combination.
• PBM incentive design: Bids and rebate structures can penalize branded products as soon as an equivalent is available.
• Dermatology vs primary care behavior: Dermatologists may sustain branded use based on experience, but primary care prescribing typically aligns more tightly to formulary status.

What generic entry risks exist for Onexton?

The highest generic entry risk is direct ANDA competition for the combination gel and indirect risk via payer switching to separate actives. Even if the fixed-dose combination remains protected longer, antibiotic-containing alternatives and benzoyl peroxide strategies can dilute Onexton share.

What would drive the fastest erosion?

• Multiple ANDA filers targeting the same combination
• Broad formulary inclusion of a lower-priced equivalent
• High switching velocity at pharmacy level
• Public guidance and stewardship that favors non-antibiotic regimens, reducing the addressable antibiotic phase

What is Onexton’s FDA regulatory status and pathway history?

For branded topical products:

• The NDA approval date and any supplements can influence exclusivity attribution.
• Label scope and any post-marketing safety communications affect prescribing comfort and market access.

No FDA approval date, NDA identifiers, or supplement history are included in this prompt, so regulatory milestone sequencing cannot be provided.

What commercial metrics should be monitored to track Onexton’s financial trajectory?

For a topical dermatology product, the business-critical scoreboard is:

• TRx and script-to-prescriber conversion: Determines whether the product is gaining or losing dermatology and primary care share.
• Net sales versus gross-to-net: Rebates and chargebacks often drive margin more than list price.
• Persistence and refill rates: Benzoyl peroxide-related irritation typically limits persistence in acne.
• Formulary tier placement by PBMs: A tier move can create a step-function change in demand.
• Channel mix: Specialty pharmacy distribution is less typical for topicals than systemic drugs, but pharmacy benefit design still controls availability and switch rates.

Revenue outlook: what is the direction of the financial trajectory?

Directionally, Onexton’s financial trajectory should be expected to trend down from a mature branded baseline if direct combination-gel equivalents or economically substitutable regimens become preferred under PBM contracts. Absent confirmed exclusivity end-date specifics, the operational forecast is driven by standard topical acne lifecycle mechanics:

• Volume stability early in the cycle: Continued guideline use and prescriber familiarity support baseline TRx.
• Margin compression over time: Even with branded persistence, net-to-gross compresses through rebates and formulary pressure.
• Accelerated erosion near exclusivity expiry: Fixed-dose combination products typically face a measurable unit decline once substitution is payer-supported.

Key Takeaways

• Onexton competes in a crowded topical acne market where payer formulary status and antibiotic stewardship dynamics drive prescribing more than differentiated mechanism alone.
• The financial trajectory is most sensitive to when fixed-dose combination protection weakens and whether payers pivot to generic combination equivalents or separate-ingredient regimens.
• The revenue path typically shows a plateau followed by margin compression and a sharper unit decline around generic entry or formulary tier downgrades.
• Monitoring TRx, persistence, net sales/gross-to-net, and PBM tier placement is the fastest way to detect whether erosion is accelerating.

FAQs

1. How do PBM formularies typically manage clindamycin-based topical acne combinations like Onexton?
2. What is the typical time lag between FDA generic approvals and real-world switch to lower-priced topical acne equivalents?
3. How do stewardship policies affect uptake and reimbursement for topical antibiotic plus benzoyl peroxide products?
4. What commercial signals indicate whether Onexton is losing market share to fixed-dose combination competitors versus multi-product regimens?
5. How should investors and licensors model margin compression risk for branded topical dermatology products?

References

No sources were cited because no Orange Book, FDA, litigation, pricing, or financial statement data were provided in the prompt.